Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

cabotamig (ARB202)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Arbele

Drug class:

CD3 agonist, CDH17 inhibitor

Related drugs:

‹

CDH17 CAR-NK cell therapy (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

ABBV-383 IV (0)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

huCD33-BsAb (0)

CDH17 CAR-NK cell therapy (0)

›

over2years

Treatment of ARB202 Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)

P1, N=68, Recruiting, Arbele Pty Ltd

over 2 years ago

New P1 trial

|

IL2 (Interleukin 2)

|

CDH1 expression

|

Tecentriq (atezolizumab) • cabotamig (ARB202)